Can CBD Live up to the Hype? Rabobank Liquid Assets Podcast

Can-CBD-Live-up-to-the-Hype-Rabobank-Liquid-Assets-Podcast.jpg
Pic:getty/alexandrkravtsov (Getty Images/iStockphoto)

CBD is the most exciting and perhaps controversial new ingredient in decades: and this guest podcast from Rabobank looks at whether it's going to be a big deal - or a big disappointment.

Despite a government crackdown on illegal sales, consumers are clamoring for CBD-infused products. This podcast from Rabobank explores what is driving demand for CBD, and  lays out the best - and worst - case scenarios for the development of the CBD market.

This episode - which you can listen to below - features Global Strategist Stephen Rannekleiv, Senior Analyst Jim Watson, and Analyst Bourcard Nesin.

Major topics Covered in the Episode:

  1. What is the legal situation for CBD in food and beverage products, and if CBD is illegal, why is the FDA allowing companies to sell it?
  2. Why do consumers want CBD? From treating medical conditions to a perceived health halo.
  3. The headwinds that could sabotage CBD: the taste of cannabis products; whether purported benefits can be proven; and its regulatory status.
  4. What opportunities are driving companies to take the risk of selling illegal products?